Efficacy and safety of immunotherapy rechallenge in second-line treatment after failure of first-line immune checkpoint inhibitors combined with chemotherapy in advanced gastric cancer: a retrospective study.

ABSTRACT:

Background

Gastric cancer is one of the most common malignant tumors worldwide, ranking fifth in incidence and fourth in mortality. While immune checkpoint inhibitor (ICI) combined chemotherapy has become the standard first-line treatment for advanced gastric cancer (AGC), most patients eventually experience disease progression. Currently, there is no unified consensus on second-line treatment strategies following failure of ICI combined chemotherapy. Immunotherapy rechallenge has shown potential efficacy in non-small cell lung cancer and melanoma, but its efficacy in AGC remains unclear. This retrospective study analyzed the effectiveness and safety of immunotherapy rechallenge versus chemotherapy in second-line treatment for AGC patients.

Methods

We retrospectively analyze

SUBMITTER: Li F 

PROVIDER: S-EPMC12728067 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature